Insider Stakes €1.7 Million on Bayer as Antitrust and Glyphosate Storms Converge

Insider purchase of €1.69M in Bayer shares signals confidence as stock hits new lows, facing antitrust lawsuits, DOJ probe, and pending Roundup Supreme Court ruling.

A Bayer supervisory board member has placed a €1.69 million bet on the company’s shares at a moment when the stock is plumbing new lows and legal troubles are piling up on two fronts. The insider purchase, executed through SF Investment One Pte Ltd — an entity closely tied to board member Marcel Smits — came on 2 June at an average price of €33.83, just as the stock plunged 5.4% to a session low of €32.90 and breached the psychologically important €34 threshold.

The timing could not be starker. On the same day, Bayer shares extended their weekly decline to nearly 11%, sliding further below the 200-day moving average of roughly €35.73. The stock recently closed at €33.96, around 5% under that long-term trendline — a technical sell signal that adds to the pressure from the 20- and 50-day lines, which had already given way. Year to date, the shares have shed more than 10%, leaving them about 31% below the 52-week high of €49.93 set in February.

While the insider purchase signals confidence that the market has undervalued the stock, the headwinds show little sign of easing. At the US district court, a new antitrust lawsuit accuses Bayer CropScience of monopolising the market for genetically modified maize seeds, specifically through its NK603 Roundup-resistant trait. Nearly 92% of US maize acreage uses herbicide-tolerant seeds, and almost all carry Bayer’s NK603 trait. Seed company Latham alleges that even after the patent on NK603 expired in 2022, Bayer continued collecting licence fees and prevented independent firms from using the trait freely, in violation of the Sherman and Clayton Acts. Latham is seeking treble damages. Bayer has denied the claims and vowed to defend itself in court.

The civil suit arrives as Bayer is already grappling with a US Department of Justice antitrust investigation. In May, the company agreed to changes in its “Premier Performance Program”, eliminating the requirement that independent seed firms meet volume targets to earn rebates — a practice that bundled maize and soybean seeds and raised regulatory concerns. Bayer committed to not reintroducing the practice for seven years. Yet the DOJ made clear its broader probe into the agricultural seed market remains active, leaving the antitrust cloud intact.

Beyond the competition cases, Bayer is waiting on a pivotal Supreme Court decision in the Durnell case, expected this month. The ruling could determine the legal foundation for thousands of pending Roundup liability lawsuits. A favourable outcome for Bayer would strip many glyphosate claims of their legal basis, offering a potential catalyst for the stock. Conversely, an adverse ruling would deepen the litigation burden that has already weighed heavily on cash flow.

The financial toll is evident. In the first quarter of 2026, Bayer generated €13.41 billion in revenue — a decline of roughly 2.5% year on year — but posted a negative free cash flow of €2.3 billion, largely driven by payouts for legal settlements. Net financial debt swelled to €32.5 billion as of 31 March. Adjusted earnings per share came in at €2.71 for the quarter, and the company has guided for full-year 2026 adjusted EPS of between €4.10 and €4.60 on revenue of €44.5 billion to €46.5 billion.

Until the cash drain from legal liabilities eases and the debt load begins to shrink, the valuation remains a balancing act. The insider’s €1.69 million vote of confidence may mark a floor — but whether it holds depends on how quickly Bayer can clear its legal hurdles, from the Supreme Court to the antitrust courtroom.